Drug intelligence / Profile preview

NIC-S

Development stage: Unknown
Lead developer: Enorama Pharma
Modality: Small Molecules
Administration: Oral, Buccal, Sublingual

Overview

NIC-S is a tobacco-free nicotine replacement therapy (NRT) product developed by Enorama Pharma. It contains pharmaceutical-grade synthetic S-type nicotine and is delivered via moist oral pouches for buccal and sublingual absorption. Designed as an over-the-counter (OTC) consumer product, it aims to assist in smoking cessation and manage nicotine dependence by providing a controlled dose of nicotine to reduce withdrawal symptoms and cravings without the use of tobacco. It is marketed in the United States through an exclusive distribution partnership with Premier Manufacturing.

Brand names: NIC-SNIC-S Nicotine Pouches
Other names: NIC-S® Nicotine Pouches

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on NIC-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIC-S.

Explore the full profile